Diagnostic Center | March 21, 2023
Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing
All children (100%) in the presymptomatic intravenous cohort of LT-002 maintained or achieved all assessed motor milestones, including independent walking
